Compass Therapeutics, Inc.
Compass Therapeutics, Inc.（CMPX）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · CMPX · 截至 2025年9月30日
股东结构概览
128
机构持有人数
▲ 22 vs Q2
$528.69M
机构持仓总市值
▲ $247.24M vs Q2
138.29M
总流通股
freeFloat 70.17%
151.05M
13F 申报持股数
▲ 42.80M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
CMPX 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 16.81M | 12.16% | 12.16% | $58.84B | Nov 14, 2025 | ▲ 3.32M |
ORBIMED ADVISORS LLC biological products, (no diagnostic substances) | 15.22M | 11.01% | 11.01% | $53.27B | Nov 14, 2025 | — held |
SUVRETTA CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 14.10M | 10.20% | 10.20% | $49.35B | Nov 14, 2025 | ▲ 6.95M |
BLACKSTONE INC. biological products, (no diagnostic substances) | 9.84M | 7.12% | 7.12% | $34.44B | Nov 14, 2025 | ▼ 185.0K |
VIVO CAPITAL, LLC biological products, (no diagnostic substances) | 9.55M | 6.90% | 6.90% | $33.41B | Nov 14, 2025 | ▲ 3.50M |
ENAVATE SCIENCES GP, LLC biological products, (no diagnostic substances) | 7.79M | 5.63% | 5.63% | $27.26B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 7.37M | 5.33% | 5.33% | $25.80B | Nov 12, 2025 | ▲ 957.6K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 7.06M | 5.11% | 5.11% | $24.72B | Nov 7, 2025 | ▲ 2.21M |
ADAGE CAPITAL PARTNERS GP, L.L.C. biological products, (no diagnostic substances) | 5.19M | 3.75% | 3.75% | $18.15B | Nov 14, 2025 | ▲ 761.6K |
BIOIMPACT CAPITAL LLC biological products, (no diagnostic substances) | 5.08M | 3.67% | 3.67% | $17.77B | Nov 14, 2025 | ▼ 546.5K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
24
增持
+29.60M 股11
新建仓
首次建仓11
减持
−2.33M 股0
清仓
完全退出净股数变化（前50家）
+27.27M
+29.60M / −2.33M
净新增持仓人
+24
新建 11 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
CMPX 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
4
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Lerner Neil Chief Accounting Officer | Apr 29, 2026 | Purchase | 15,000 | $1.89 | $28.4K | 397.5K | Form 4 ↗ |
Anderman Jonathan General Counsel | Apr 29, 2026 | Purchase | 25,000 | $1.89 | $47.3K | 196.0K | Form 4 ↗ |
Anderman Jonathan General Counsel | Apr 29, 2026 | Award | 25,000 | $1.89 | $47.3K | 196.0K | Form 4 ↗ |
Lerner Neil Chief Accounting Officer | Apr 29, 2026 | Award | 15,000 | $1.89 | $28.4K | 397.5K | Form 4 ↗ |
Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Feb 8, 2026 | Tax Withhold | 36,687 | $6.52 | $239.2K | 6.60M | Form 4 ↗ |
Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Jan 9, 2026 | Tax Withhold | 46,777 | $5.35 | $250.3K | 6.64M | Form 4 ↗ |
Shin Barry CFO | Jan 2, 2026 | Award | 670,000 | $5.17 | $3.46M | 670.0K | Form 4 ↗ |
Shin Barry CFO | Jan 2, 2026 | Award | 125,000 | $5.17 | $646.3K | 525.0K | Form 4 ↗ |
Sirard Cynthia Chief Medical Officer | Jan 2, 2026 | Award | 1,000,000 | $5.17 | $5.17M | 1.00M | Form 4 ↗ |
Schuetz Thomas J. CEO | Jan 2, 2026 | Award | 250,000 | $5.17 | $1.29M | 6.69M | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Compass Therapeutics, Inc.（CMPX）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 29.83%，散户及公众持股约占剩余的 0.00%。
Compass Therapeutics, Inc. 最大机构股东为 TANG CAPITAL MANAGEMENT LLC，截至 September 30, 2025 持有约 16.81 million 股，占总流通股的 12.16%。
目前共有 128 家机构持有 CMPX 股票，合计持仓市值约 $528,694,354，数据来源为最新 SEC 13F 申报。
常见问题
CMPX ownershipCompass Therapeutics, Inc.（CMPX）主要由机构投资者持有，机构持股约 100.0%。最大股东为 TANG CAPITAL MANAGEMENT LLC，持股比例 12.16%。内部人员持股约 29.83%。数据来源 SEC Form 13F，截至 September 30, 2025。